Meeting Minutes: Drug Formulary Committee

Date & Time: May 22, 2018, 5-9 PM
Minutes prepared by: Hind Douiki, Nina Bandali, and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., Ph.D., Al Heaton, RPh., Kyle Lehenbauer, M.D., Kathryn Lombardo, M.D., Stacey Ness, Pharm.D., James Phillips, M.D., Kelly Ruby, Pharm.D, Michael Sprehe, M.D., Stuart Williams, J.D.
- Members absent: Monica Brands, RPh.
- DHS staff present: Jeff Schiff, M.D., MBA, Chad Hope, Pharm.D., Dave Hoang, Pharm.D., MBA, Mary Beth Reinke, Pharm.D., MSA.
- Others in attendance: Nina Bandali, Pharm.D., Hind Douiki, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair

No new report

Approval of Minutes

Minutes from the January 2018 meeting were reviewed and approved.

New Business

- Hind Douiki from Magellan introduced herself to the committee as Nina Bandali’s replacement.
- Reappointed members are introduced: Kelly Ruby, Kathryn Lombardo, Michael Sprehe, and Monica Brands

New Specialty Drugs for Continued PA

- The committee discussed Luxturna and recommended to the department by a unanimous vote that Luxturna remain on PA with the following revisions:
  - Change in patient’s age from at least 4 years old to at least 12 months old
  - Removal of Leber Congenital Amaurosis type 2 (LCA2)
  - Addition of: significant visual loss if patient is unable to complete one or both assessments in bullet #7
The committee discussed Mepsevii and recommended to the department by a unanimous vote that Mepsevii remain on PA with an additional criterion of consultation with a metabolic or genetic specialist.

The committee discussed Ozempic and recommended to the department by a unanimous vote that Ozempic remain on PA. Dave also stated that Victoza will be changed to preferred status on the PDL due to its cardiovascular benefits.

The committee discussed Prevymis and recommended to the department by a unanimous vote that Prevymis remain on PA with an additional criterion of contraindication to, or treatment failure of, ganciclovir.

The committee discussed Fasenra and recommended to the department by a unanimous vote that Fasenra remain on PA.

The committee discussed Calquence and recommended to the department by a unanimous vote that Calquence remain on PA.

The committee discussed Aliqopa and recommended to the department by a unanimous vote that Aliqopa remain on PA.

The committee discussed Besponsa and recommended to the department by a unanimous vote that Besponsa remain on PA with the following revisions:
  - Combining the repetitive parts of bullet #2 and bullet #7
  - Combining the repetitive parts of bullet #3 and bullet #7’s second sub-bullet

New Drugs for Continued PA

The committee discussed Steglatro and recommended to the department by a unanimous vote that Steglatro remain on PA. Dave also indicated that Invokana, Farxiga, and Jardiance will be preferred on the PDL.

The committee discussed Endari and recommended to the department by a unanimous vote that Endari remain on PA with an additional criterion of treatment failure of OTC glutamine (if commercially available and can be covered per MN regulation).

The committee discussed Baxdela and recommended to the department by a unanimous vote that Baxdela remain on PA.

The committee discussed Vyzulta and recommended to the department by a unanimous vote that Vyzulta remain on PA with an additional criterion of treatment failure of an ophthalmic beta blocker agent.

The committee discussed Gocovri and recommended to the department by a unanimous vote that Gocovri remain on PA.

The committee discussed Solosec and recommended to the department by a unanimous vote that Solosec remain on PA with an additional criterion of providing rationale as to why metronidazole, clindamycin, or tinidazole cannot be used.

The committee discussed Admelog and recommended to the department by a unanimous vote that Admelog remain on PA.
Adjournment

- Dave stated that the next DFC meeting will likely take place during the week of September 17, 2018.
- The meeting was adjourned at 8:39 PM Central Time.